16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor associated inflammation predicts response to immune checkpoint blockade in human melanoma. Current theories on regulation of inflammation center on anti-tumor T cell responses. Here we show that tumor associated B cells are vital to melanoma associated inflammation. Human B cells express pro- and anti-inflammatory factors and differentiate into plasmablast-like cells when exposed to autologous melanoma secretomes in vitro. This plasmablast-like phenotype can be reconciled in human melanomas where plasmablast-like cells also express T cell-recruiting chemokines CCL3, CCL4, CCL5. Depletion of B cells in melanoma patients by anti-CD20 immunotherapy decreases tumor associated inflammation and CD8 + T cell numbers. Plasmablast-like cells also increase PD-1 + T cell activation through anti-PD-1 blockade in vitro and their frequency in pretherapy melanomas predicts response and survival to immune checkpoint blockade. Tumor associated B cells therefore orchestrate and sustain melanoma inflammation and may represent a predictor for survival and response to immune checkpoint blockade therapy.

          Abstract

          The regulation of tumor inflammation is incompletely understood and the role of B cells is unclear. Here, the authors show that a specific subtype of B cells is induced in melanoma and required to recruit T lymphocytes and elicit inflammation.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

          Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth. ©2011 Macmillan Publishers Limited. All rights reserved
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

            Clinical trials with immune checkpoint inhibitors have provided important insights into the mode of action of anticancer immune therapies and potential mechanisms of immune escape. Development of the next wave of rational clinical combination strategies will require a deep understanding of the mechanisms by which combination partners influence the battle between the immune system's capabilities to fight cancer and the immune-suppressive processes that promote tumor growth. This review focuses on our current understanding of tumor and circulating pharmacodynamic correlates of immune modulation and elaborates on lessons learned from human translational research with checkpoint inhibitors. Actionable tumor markers of immune activation including CD8(+)T cells, PD-L1 IHC as a pharmacodynamic marker of T-cell function, T-cell clonality, and challenges with conduct of trials that ask scientific questions from serial biopsies are addressed. Proposals for clinical trial design, as well as future applications of peripheral pharmacodynamic endpoints as potential surrogates of early clinical activity, are discussed. On the basis of emerging mechanisms of response and immune escape, we propose the concept of the tumor immunity continuum as a framework for developing rational combination strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

              Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be fully explained by genomic mechanisms and may be accompanied by co-evolution of intra-tumoral immunity. We sought to discover non-genomic mechanisms of acquired resistance and dynamic immune compositions by a comparative, transcriptomic-methylomic analysis of patient-matched melanoma tumors biopsied before therapy and during disease progression. Transcriptomic alterations across resistant tumors were highly recurrent, in contrast to mutations, and were frequently correlated with differential methylation of tumor cell-intrinsic CpG sites. We identified in the tumor cell compartment supra-physiologic c-MET up-expression, infra-physiologic LEF1 down-expression and YAP1 signature enrichment as drivers of acquired resistance. Importantly, high intra-tumoral cytolytic T cell inflammation prior to MAPKi therapy preceded CD8 T cell deficiency/exhaustion and loss of antigen presentation in half of disease-progressive melanomas, suggesting cross-resistance to salvage anti-PD-1/PD-L1 immunotherapy. Thus, melanoma acquires MAPKi resistance with highly dynamic and recurrent non-genomic alterations and co-evolving intra-tumoral immunity.
                Bookmark

                Author and article information

                Contributors
                +43 1 40400 77020 , johannes.griss@meduniwien.ac.at
                +43 1 40400 77020 , stephan.wagner@meduniwien.ac.at
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                13 September 2019
                13 September 2019
                2019
                : 10
                : 4186
                Affiliations
                [1 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Department of Dermatology, , Medical University of Vienna, ; 1090 Vienna, Austria
                [2 ]EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, CB10 1SD Hinxton, Cambridge, UK
                [3 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, ; 1090 Vienna, Austria
                [4 ]ISNI 0000 0004 0392 6802, GRID grid.418729.1, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, ; 1090 Vienna, Austria
                [5 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Department of Laboratory Medicine, , Medical University of Vienna, ; 1090 Vienna, Austria
                [6 ]ISNI 0000 0001 1956 6678, GRID grid.251075.4, Molecular & Cellular Oncogenesis Program and Melanoma Research Center, , The Wistar Institute, ; Philadelphia, PA 19104-4265 USA
                [7 ]GRID grid.410567.1, Institute of Pathology, , University Hospital Basel, ; 4031 Basel, Switzerland
                [8 ]GRID grid.410567.1, Division of Medical Oncology, , University Hospital Basel, ; 4031 Basel, Switzerland
                [9 ]GRID grid.440128.b, Institute of Pathology, , Cantonal Hospital Baselland, ; 4410 Liestal, Switzerland
                [10 ]ISNI 0000 0001 2286 1424, GRID grid.10420.37, Mass Spectrometry Facility, Max F. Perutz Laboratories (MFPL), , University of Vienna, Vienna BioCenter (VBC), ; 1030 Vienna, Austria
                [11 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Division of Cellular Immunology and Immunohematology, Institute of Immunology, Center for Pathophysiology, , Infectiology and Immunology, Medical University of Vienna, ; 1090 Vienna, Austria
                [12 ]GRID grid.416346.2, Present Address: Children’s Cancer Research Institute, ; 1090 Vienna, Austria
                [13 ]ISNI 0000000100241216, GRID grid.189509.c, Present Address: Department of Neurosurgery & The Preston Robert Tisch Brain Tumor Center, , Duke University Medical Center, ; Durham, NC 27710 USA
                Author information
                http://orcid.org/0000-0003-2206-9511
                http://orcid.org/0000-0002-0155-1176
                http://orcid.org/0000-0003-3519-9972
                http://orcid.org/0000-0001-6091-3088
                http://orcid.org/0000-0001-8617-8886
                http://orcid.org/0000-0002-8910-5620
                http://orcid.org/0000-0001-7080-5259
                http://orcid.org/0000-0002-4970-7336
                http://orcid.org/0000-0001-6848-4097
                http://orcid.org/0000-0003-4941-7029
                Article
                12160
                10.1038/s41467-019-12160-2
                6744450
                31519915
                4bf4bd15-1276-4c4f-a47d-df8ff454f708
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 23 December 2018
                : 22 August 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100002428, Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung);
                Award ID: P31127-B28
                Award ID: SFB F4609
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100010663, EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council);
                Award ID: 788042
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                cancer microenvironment,tumour immunology,melanoma
                Uncategorized
                cancer microenvironment, tumour immunology, melanoma

                Comments

                Comment on this article